JP2002513552A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002513552A5 JP2002513552A5 JP2000547102A JP2000547102A JP2002513552A5 JP 2002513552 A5 JP2002513552 A5 JP 2002513552A5 JP 2000547102 A JP2000547102 A JP 2000547102A JP 2000547102 A JP2000547102 A JP 2000547102A JP 2002513552 A5 JP2002513552 A5 JP 2002513552A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- seq
- interacting
- inhibiting
- activation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000018102 proteins Nutrition 0.000 description 29
- 102000004169 proteins and genes Human genes 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 29
- 230000002401 inhibitory effect Effects 0.000 description 9
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 239000012634 fragment Substances 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98201472 | 1998-05-06 | ||
| EP98201472.2 | 1998-05-06 | ||
| PCT/BE1999/000055 WO1999057133A2 (en) | 1998-05-06 | 1999-05-05 | Inhibitors of nf-kb activation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002513552A JP2002513552A (ja) | 2002-05-14 |
| JP2002513552A5 true JP2002513552A5 (enExample) | 2006-05-11 |
Family
ID=8233686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000547102A Pending JP2002513552A (ja) | 1998-05-06 | 1999-05-05 | ＮＦ−κＢ活性化の新規な阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6673897B1 (enExample) |
| EP (1) | EP1075519B1 (enExample) |
| JP (1) | JP2002513552A (enExample) |
| AT (1) | ATE309352T1 (enExample) |
| AU (1) | AU754434B2 (enExample) |
| CA (1) | CA2328483A1 (enExample) |
| DE (1) | DE69928244T2 (enExample) |
| ES (1) | ES2251831T3 (enExample) |
| WO (1) | WO1999057133A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2328483A1 (en) | 1998-05-06 | 1999-11-11 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Inhibitors of nf-kb activation |
| GB9930616D0 (en) * | 1999-12-24 | 2000-02-16 | Mathilda & Terence Kennedy Ins | Activation and inhibition of the immune system |
| WO2003000280A2 (en) * | 2001-06-22 | 2003-01-03 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Abin-mediated hepatitis protection |
| WO2005027959A1 (en) | 2003-09-24 | 2005-03-31 | Institut Pasteur | Selective inhibition of nf-kappab activation by peptides designed to disrupt nemo oligomerization. |
| WO2006029981A1 (en) * | 2004-09-13 | 2006-03-23 | Vib Vzw | Abin-mediated protection against lung inflammatory disease |
| CN1304418C (zh) * | 2005-02-22 | 2007-03-14 | 中国人民解放军第三军医大学第三附属医院 | 核因子－κB p65亚基拮抗肽及其应用 |
| US7893026B2 (en) | 2005-04-14 | 2011-02-22 | Vib Vzw | Treatment of EGFR-dependent tumors by ABIN (a20 -binding inhibitor of NF kappab) |
| EP3270158B1 (en) * | 2006-10-30 | 2019-05-01 | Centre National de la Recherche Scientifique (CNRS) | Gene reporter assay, kit and cells with improved sensitivity and/or specificity for determining the level of tnf-gamma |
| CN101307094B (zh) * | 2008-03-21 | 2011-09-28 | 中国人民解放军第三军医大学第三附属医院 | 一种核因子-κB p65亚基拮抗多肽 |
| CN101798336B (zh) * | 2009-02-06 | 2012-02-29 | 中国人民解放军第三军医大学第三附属医院 | 一种具有示踪功能的抗肿瘤化合物 |
| CN111606976A (zh) * | 2020-05-26 | 2020-09-01 | 中国人民解放军军事科学院军事医学研究院 | 一种小肽及其在抑制阿片成瘾性和耐受性上的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| UA71889C2 (uk) * | 1996-04-02 | 2005-01-17 | Йєда Рісерч Енд Дівелопмент Ко. Лтд. | Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування |
| CA2328483A1 (en) | 1998-05-06 | 1999-11-11 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Inhibitors of nf-kb activation |
-
1999
- 1999-05-05 CA CA002328483A patent/CA2328483A1/en not_active Abandoned
- 1999-05-05 ES ES99924594T patent/ES2251831T3/es not_active Expired - Lifetime
- 1999-05-05 AT AT99924594T patent/ATE309352T1/de not_active IP Right Cessation
- 1999-05-05 EP EP99924594A patent/EP1075519B1/en not_active Expired - Lifetime
- 1999-05-05 JP JP2000547102A patent/JP2002513552A/ja active Pending
- 1999-05-05 DE DE69928244T patent/DE69928244T2/de not_active Expired - Lifetime
- 1999-05-05 AU AU41244/99A patent/AU754434B2/en not_active Ceased
- 1999-05-05 WO PCT/BE1999/000055 patent/WO1999057133A2/en not_active Ceased
-
2000
- 2000-10-31 US US09/702,953 patent/US6673897B1/en not_active Expired - Fee Related
-
2003
- 2003-10-08 US US10/680,998 patent/US7414026B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002513552A5 (enExample) | ||
| AU1313095A (en) | Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbb plays a role | |
| EP1354598A3 (en) | Therapeutic uses of BR43X2 soluble receptors | |
| WO1999006066A3 (en) | Catalytic monoclonal antibodies with protease activity for the selective lysis of the protein component of plaques and aggregates related to pathological conditions | |
| NO20091888L (no) | Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav | |
| HK1043134A1 (zh) | 免疫球蛋白e的c-易扑西龍-3或者c-易扑西龍-4區衍生來的抗原決定基或模擬型，其拮抗劑，以它們的治療用途 | |
| JP2020528447A5 (enExample) | ||
| EP1398029A8 (en) | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives | |
| WO2004013287A3 (en) | Antibodies against c3a receptor | |
| WO2001043691A3 (en) | Fragments and antagonists of heat shock protein 60 | |
| WO2003081258A3 (en) | Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs) | |
| JP2003511346A5 (enExample) | ||
| WO2001081328A3 (en) | Thiazolidinedione analogues and their use for the treatment of diabetes | |
| WO2003042367A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
| WO2001055410A3 (en) | Ceramidase compositions and methods based thereon | |
| WO2004042402A3 (en) | Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1) | |
| WO2002044737A3 (en) | Diagnostic and therapeutic compositions and methods related to anaphylatoxin c3a receptor | |
| WO2003048193A3 (en) | GIPs, A FAMILY OF POLYPEPTIDES WITH TRANSCRIPTION FACTOR ACTIVITY THAT INTERACT WITH GOODPASTURE ANTIGEN BINDING PROTEIN | |
| CN100341566C (zh) | 芋螺多肽衍生物用于制备戒毒药物的用途 | |
| WO2001057534A3 (en) | Compositions and methods for reducing autoimmunity | |
| WO2002070563A3 (en) | Nuclear hormone receptor ligand binding domain | |
| WO2004071378A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a) | |
| WO2004099783A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4) | |
| WO2004048978A3 (en) | Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37) | |
| WO2004104577A3 (en) | Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4) |